About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis

NCT03138525·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Brigham and Women's Hospital

With

Genentech, Inc.

Age

18–60

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Patients with relapsing form of MS starting treatment with ocrelizumab at Partners MS Center
Healthy controls
Ability to understand and sign informed consent

You may not be if

Other concomitant autoimmune or inflammatory diseases
Ongoing treatment with other immunomodulatory medications
Previous treatment with rituximab, methotrexate, cyclophosphamide, mitoxantrone, mycophenolate mofetil, or alemtuzumab
Pregnancy or lactation
Hypersensitivity to ocrelizumab
MS
First-degree relatives with MS

The record

StatusCompleted

PhaseNo phase

Taking part161

StartedJun 2017

UpdatedJan 27, 2021

Conditions

Multiple Sclerosis Healthy

Where1

Brigham and Women's Hospital
Boston, Massachusetts, United States

Clareo Health | Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis